FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

| · · · · · · · · · · · · · · · · · · · | ., | |
|---------------------------------------|----|--|
| | | |
| | | |

| 1 | OIVID APPROVAL | | | | | | | | | |
|---|----------------------|-----------|--|--|--|--|--|--|--|--|
| | OMB Number: | 3235-0287 | | | | | | | | |
| | Estimated average bu | ırden | | | | | | | | |

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* McFarlane Neil F. | | | | | 2. Issuer Name and Ticker or Trading Symbol Retrophin, Inc. [RTRX] | | | | | | | | (Ch | eck all applic Directo | '' / | | rson(s) to Issuer 10% Owner Other (specify | | |
|---|--|------------|---|-----------------|--|---|-----------------------------|-----|---|-------------|--------------------|--|--|--|--|--------------------|--|--|--|
| (Last) C/O RETR | | C. | fiddle) | | 3. Date of Earliest Transaction (Month/Day/Year) 05/10/2018 | | | | | | | | | X Office (give title Other (specify below) Chief Operating Officer | | | | | |
| 3721 VALLEY CENTRE DR., SUITE 200 | | | | | | If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | |
| (Street) SAN DIEGO CA 92130 | | | | | The state of the s | | | | | | | Lin | | | | | | | |
| (City) | (Stat | | ip) | Davis | | | | Λ | | D: | | Da | - £: - : - !! | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | Execution Date, | | | 3. Transaction Code (Instr. | | ies Acquired (A) or Of (D) (Instr. 3, 4 an | | 5. Amoui | For lly (D) ollowing (I) (| | m: Direct I or Indirect I Instr. 4) | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Transact (Instr. 3 a | ion(s) | | | (Instr. 4) | |
| Common Stock 05/10. | | | | 0/2018 | 2018 | | A | | 10,500 | 10,500 A \$ | | 0 27, | 27,948 | | D | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Yea | | 3A. Deeme Execution if any (Month/Da | Date, | 4. Transaction Code (Instr. 8) | | n of | | 6. Date Exercisa Expiration Date (Month/Day/Yea | | е | 7. Title an of Securit Underlyin Derivative (Instr. 3 ai | ies g Security | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4) | e s Ily J | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisa | | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Employee stock option (right to buy) | \$25.25 | 05/10/2018 | | | A | | 63,000 | | (1) | | 05/09/2028 | Common Stock | 63,000 | \$0.00 | 63,00 | 0 | D | | |
| Performance- based restricted | (2) | 05/10/2018 | | | A | | 10,500 | | (3) | | (3) | Common Stock | 10,500 | \$0.00 | 10,50 | 0 | D | | |

Explanation of Responses:

- 1. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
- 2. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- 3. This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date.

Remarks:

/s/ Elizabeth E. Reed, Attorney-05/14/2018 in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.